Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Blood (2022) 140 (21): 2248–2260.

https://doi.org/10.1182/blood.2022015478

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study

Tove Wästerlid, Anna Warnqvist, Caroline E. Weibull, Björn E Wahlin, P-O Andersson, Gunilla Enblad, Eva Kimby, Karin Ekstroem Smedby

Blood (2022) 140 (Supplement 1): 3620–3621.

https://doi.org/10.1182/blood-2022-164550

Published: 2022

Journal Articles

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Stefano Luminari, Alexander Fosså, Judith Trotman, Daniel Molin, Francesco Annibale d'Amore, Gunilla Enblad, Leanne Berkahn, Sally F Barrington, John Radford, Massimo Federico, Amy A. Kirkwood, Peter Johnson

Blood (2022) 140 (Supplement 1): 766–767.

https://doi.org/10.1182/blood-2022-162780

Published: 2022

Journal Articles

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Blood (2021) 138 (Supplement 1): 430.

https://doi.org/10.1182/blood-2021-147598

Published: 2021

Journal Articles

Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden

Caroline Weibull, Björn E Wahlin, MD PhD, Sandra Lockmer, Gunilla Enblad, Per-Ola Andersson, MD PhD, Eva Kimby, MD PhD, Karin E. Smedby, MD PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140228

Published: 2020

Journal Articles

Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden

Karin Ekstroem Smedby, Sara Harrysson, MD, Sara Ekberg, Mats Jerkeman, MD PhD, Per-Ola Andersson, MD PhD, Gunilla Enblad, Sandra Eloranta

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-138737

Published: 2020

Journal Articles

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Sara Harrysson, MD, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, MD Professor, Sverker Hasselblom, Björn E Wahlin, MD PhD, Per-Ola Andersson, MD PhD, Karin E. Smedby, MD PhD

Blood (2019) 134 (Supplement_1): 399.

https://doi.org/10.1182/blood-2019-122014

Published: 2019

Journal Articles

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Karin Ekstrom Ekstroem Smedby, Sara Ekberg, Sandra Eloranta, Gunilla Enblad, Mats Jerkeman, MD Professor, Per-Ola Andersson, MD PhD, Sara Harrysson, MD

Blood (2019) 134 (Supplement_1): 4111.

https://doi.org/10.1182/blood-2019-123785

Published: 2019

Journal Articles

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Susanne Bram Ednersson, MD, Mimmie Stern, MD, Henrik Fagman, Gunilla Enblad, Ulf-Henrik Mellqvist, MD PhD, Herman Nilsson-Ehle, MD PhD, Sverker Hasselblom, Per-Ola Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3967.

https://doi.org/10.1182/blood-2019-126387

Published: 2019

Journal Articles

Outcome and Determinants of Failure to Complete 6-8 Cycles of Primary R-CHOP Treatment for Reasons Unrelated to Progression Among Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Karin Ekstrom Smedby, MD PhD, Sara Harrysson, MD, Per-Ola Andersson, Gunilla Enblad, Sara Ekberg, Mats Jerkeman, Sandra Eloranta

Blood (2018) 132 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2018-99-116343

Published: 2018

Journal Articles

Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden

Sara Harrysson, MD, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, Sverker Hasselblom, Björn E Wahlin, Per-Ola Andersson, Karin E Smedby

Blood (2018) 132 (Supplement 1): 2975.

https://doi.org/10.1182/blood-2018-99-110672

Published: 2018

Journal Articles

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Tove Wästerlid, MD PhD, Jorne Lionel Biccler, MSc, Peter de Nully Brown, MD PhD, Jacob Haaber Christensen, MD PhD, Gunilla Enblad, MD PhD, Judit Mészáros Jørgensen, Karin E Smedby, MD PhD, Tarec Christoffer El-Galaly, MD PhD, Mats Jerkeman, MD PhD

Blood (2017) 130 (Supplement 1): 1560.

https://doi.org/10.1182/blood.V130.Suppl_1.1560.1560

Published: 2017

Journal Articles

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Larry Mansouri, Daniel Noerenberg, Emma Young, Elena Mylonas, Maysaa Abdulla, Mareike Frick, Fazila Asmar, Viktor Ljungström, Markus Schneider, Kenichi Yoshida, Aron Skaftason, Tatjana Pandzic, Blanca Gonzalez, Anna Tasidou, Nils Waldhueter, Alfredo Rivas-Delgado, Maria Angelopoulou, Marita Ziepert, Christopher Maximilian Arends, Lucile Couronné, Dido Lenze, Claudia D. Baldus, Christian Bastard, Jessica Okosun, Jude Fitzgibbon, Bernd Dörken, Hans G. Drexler, Damien Roos-Weil, Clemens A. Schmitt, Helga D. Munch-Petersen, Thorsten Zenz, Martin-Leo Hansmann, Jonathan C. Strefford, Gunilla Enblad, Olivier A. Bernard, Elisabeth Ralfkiaer, Martin Erlanson, Penelope Korkolopoulou, Magnus Hultdin, Theodora Papadaki, Kirsten Grønbæk, Armando Lopez-Guillermo, Seishi Ogawa, Ralf Küppers, Kostas Stamatopoulos, Niki Stavroyianni, George Kanellis, Andreas Rosenwald, Elias Campo, Rose-Marie Amini, German Ott, Theodoros P. Vassilakopoulos, Michael Hummel, Richard Rosenquist, Frederik Damm

Blood (2016) 128 (23): 2666–2670.

https://doi.org/10.1182/blood-2016-03-704528

Published: 2016

Includes: Supplemental data

Journal Articles

Overexpression of Ribosomal Proteins Is Associated with Resistance to Immunochemotherapy in Diffuse Large B-Cell Lymphoma Patients

Martin Stenson, MD, Susanne Bram-Ednersson, MD, Herman Nilsson-Ehle, MD PhD, Mimmie Stern, MD, Gunilla Enblad, Sverker Hasselblom, MD PhD, Per-Ola Andersson, MD PhD

Blood (2016) 128 (22): 4121.

https://doi.org/10.1182/blood.V128.22.4121.4121

Published: 2016

Journal Articles

ΝFΚΒΙΕ Deletions : A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma

Daniel Noerenberg*, Larry Mansouri*, Emma Young, Frick Mareike, Maysaa Abdulla, Fazila Asmar, Blanca Gonzalez-Farre, Tasidou Anna, Nils Waldhueter, Viktor Ljungström, Alfredo Rivas, Maria K. Angelopoulou, Marita Ziepert, Christopher M. Arends, Lucile Couronne, Dido Lenze, Claudia D. Baldus, MD, Christian Bastard, Jessica Okosun, Jude Fitzgibbon, Bernd Dörken, Hans G. Drexler, Damien Roos-Weil, Clemens A. Schmitt, Helga Duverger Munch-Petersen, Thorsten Zenz, Jonathan C. Strefford, Gunilla Enblad, Olivier A. Bernard, Elisabeth Ralfkiaer, Penelope Korkolopoulou, Magnus Hultdin, Theodora Papadaki, Kirsten Grønbæk, Armando Lopez-Guillermo, Kostas Stamatopoulos, MD PhD, Niki Stavroyianni, George Kanellis, Andreas Rosenwald, MD, Elias Campo, Rose-Marie Amini, German Ott, Theodoros Vassilakopoulos, Michael Hummel, Frederik Damm**, Richard Rosenquist**

Blood (2016) 128 (22): 609.

https://doi.org/10.1182/blood.V128.22.609.609

Published: 2016

Journal Articles

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

Blood (2016) 127 (24): 3026–3034.

https://doi.org/10.1182/blood-2015-12-686550

Published: 2016

Includes: Supplemental data

Journal Articles

Third Generation CD19-CAR T Cells for Relapsed and Refractory Lymphoma and Leukemia Report from the Swedish Phase I/IIa Trial

Gunilla Enblad, MDPhD, Hannah Karlsson, PhD, Kristina Wikstrom, PhD, Magnus Essand, PhD, Barbara Savoldo, MD PhD, Malcolm K. Brenner, MD PhD, Gianpietro Dotti, MD, Helene Hallbook, MDPhD, Martin Hoglund, MD PhD, Hans Hagberg, MD PhD, Angelica Loskog, PhD

Blood (2015) 126 (23): 1534.

https://doi.org/10.1182/blood.V126.23.1534.1534

Published: 2015

Journal Articles

Diffusely Increased Bone Marrow 18F-FDG Uptake Is an Independent Predictor of Focal Bone Lesions in Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Lars C. Gormsen, Cecilia Wassberg, Daniel Molin, Peter Kamper, Gunilla Enblad, Francesco d'Amore

Blood (2014) 124 (21): 5360.

https://doi.org/10.1182/blood.V124.21.5360.5360

Published: 2014

Journal Articles

Recurrent Mutations within the Nfkbie gene: A Novel Mechanism for NF-κB Deregulation in Aggressive Chronic Lymphocytic Leukemia

Blood (2014) 124 (21): 297.

https://doi.org/10.1182/blood.V124.21.297.297

Published: 2014

Journal Articles

Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients

Noel F. C. C. de Miranda, Konstantinos Georgiou, Longyun Chen, Chenglin Wu, Zhibo Gao, Apostolos Zaravinos, Susana Lisboa, Gunilla Enblad, Manuel R. Teixeira, Yixin Zeng, Roujun Peng, Qiang Pan-Hammarström

Blood (2014) 124 (16): 2544–2553.

https://doi.org/10.1182/blood-2013-12-546309

Published: 2014

Includes: Supplemental data

NARROW

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden

Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Outcome and Determinants of Failure to Complete 6-8 Cycles of Primary R-CHOP Treatment for Reasons Unrelated to Progression Among Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Overexpression of Ribosomal Proteins Is Associated with Resistance to Immunochemotherapy in Diffuse Large B-Cell Lymphoma Patients

ΝFΚΒΙΕ Deletions : A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

Third Generation CD19-CAR T Cells for Relapsed and Refractory Lymphoma and Leukemia Report from the Swedish Phase I/IIa Trial

Diffusely Increased Bone Marrow 18F-FDG Uptake Is an Independent Predictor of Focal Bone Lesions in Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Recurrent Mutations within the Nfkbie gene: A Novel Mechanism for NF-κB Deregulation in Aggressive Chronic Lymphocytic Leukemia

Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only